Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spironolactone: a re-examination.

H A Skluth1, J G Gums

  • 1College of Pharmacy, Southeastern University of the Health Sciences, Miami, FL.

DICP : the Annals of Pharmacotherapy
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?

Clinical and translational science·2016
Same author

Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.

The pharmacogenomics journal·2014
Same author

Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.

Clinical pharmacology and therapeutics·2014
Same author

Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.

Journal of internal medicine·2014
Same author

Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.

The pharmacogenomics journal·2013
Same author

Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.

The pharmacogenomics journal·2012
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Spironolactone effectively controls hypertension and aids in managing conditions like cirrhosis and heart failure. At lower doses (under 150 mg/d), its side effects are typically minimal, making it a valuable therapeutic option.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Cardiology

Background:

  • Spironolactone is an aldosterone antagonist with diverse clinical applications.
  • Its efficacy in hypertension and as a diuretic is well-established.
  • It also possesses antiandrogenic properties.

Purpose of the Study:

  • To review the multifaceted therapeutic uses of spironolactone.
  • To evaluate its effectiveness in various medical conditions.
  • To assess its safety profile at different dosages.

Main Methods:

  • Literature review of clinical studies and therapeutic guidelines.
  • Analysis of spironolactone's pharmacological actions.
  • Examination of adverse effect data from clinical trials.

Related Experiment Videos

Main Results:

  • Spironolactone demonstrates efficacy in essential and hyperaldosterone-induced hypertension, both alone and with other agents.
  • It serves as a beneficial diuretic in cirrhosis and congestive heart failure, noted for its potassium- and magnesium-sparing effects.
  • The drug is also utilized for its antiandrogenic effects in hirsutism management.

Conclusions:

  • Spironolactone is a versatile medication for hypertension, edema, and hormonal conditions.
  • Its adverse effects are generally manageable, particularly at doses below 150 mg/d.
  • Reasonable dosing ensures a favorable risk-benefit ratio for spironolactone therapy.